Echocardiographic Functional Outcomes Following Regional Nodal Irradiation for Breast Cancer Using Volumetric Modulated Arc Therapy

IF 2.2 Q3 ONCOLOGY Advances in Radiation Oncology Pub Date : 2024-07-25 DOI:10.1016/j.adro.2024.101581
Anthony F. Yu MD, MS , Charlie White PhD , Zhigang Zhang PhD , Jennifer E. Liu MD , Erin F. Gillespie MD , Beryl McCormick MD , Atif J. Khan MD , Richard M. Steingart MD , Simon N. Powell MD, PhD , Oren Cahlon MD , Lior Z. Braunstein MD
{"title":"Echocardiographic Functional Outcomes Following Regional Nodal Irradiation for Breast Cancer Using Volumetric Modulated Arc Therapy","authors":"Anthony F. Yu MD, MS ,&nbsp;Charlie White PhD ,&nbsp;Zhigang Zhang PhD ,&nbsp;Jennifer E. Liu MD ,&nbsp;Erin F. Gillespie MD ,&nbsp;Beryl McCormick MD ,&nbsp;Atif J. Khan MD ,&nbsp;Richard M. Steingart MD ,&nbsp;Simon N. Powell MD, PhD ,&nbsp;Oren Cahlon MD ,&nbsp;Lior Z. Braunstein MD","doi":"10.1016/j.adro.2024.101581","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Regional nodal irradiation (RNI) for breast cancer yields improvements in disease outcomes, yet comprehensive target coverage often increases cardiac radiation therapy (RT) dose. Volumetric modulated arc therapy (VMAT) may mitigate high-dose cardiac exposure, although it often increases the volume of low-dose exposure. The cardiac implications of this dosimetric configuration (in contrast to historic 3D conformal techniques) remain uncertain.</p></div><div><h3>Methods and Materials</h3><p>Eligible patients receiving adjuvant RNI using VMAT for locoregional breast cancer were prospectively enrolled in an IRB-approved study. Echocardiograms were performed prior to RT, at the conclusion of RT, and 6 months following RT. Echocardiographic parameters were measured by a single reader and measures were compared pre- and post-RT via the signed-rank test. Changes in echocardiographic parameters over time were compared to mean and max heart doses via the Spearman correlation test.</p></div><div><h3>Results</h3><p>Among 19 evaluable patients (median age 38 years), 89% (n = 17) received doxorubicin and 37% (n = 7) received trastuzumab/pertuzumab combination therapy. All patients received VMAT-based whole-breast/chest wall and RNI. The average mean heart dose was 456 cGy (range, 187-697 cGy) and the average max heart dose was 3001 cGy (1560-4793 cGy). Among salient echocardiographic parameters, no significant decrement in cardiac function was observed when comparing pre-RT to 6 months post-RT: mean left ventricular ejection fraction (LVEF) was 61.8% (SD 4.4%) pre-RT and 62.7% (SD 3.8%) 6 months post-RT (<em>P</em> = .493); mean global longitudinal strain (GLS) was –19.3% (SD 2.2%) pre-RT and –19.6% (SD 1.8%) 6 months post-RT (<em>P</em> = .627). No individual patient exhibited reduced LVEF or sustained decrement in GLS. No correlations were observed for changes in LVEF or GLS when compared to mean or maximum heart doses (<em>P</em> &gt; .1 for all).</p></div><div><h3>Conclusions</h3><p>VMAT for left-sided RNI yielded no significant early decrement in echocardiographic parameters of cardiac function, including LVEF and GLS, within this limited cohort. No patient exhibited significant LVEF changes, and none exhibited sustained decrements in GLS. VMAT may be a reasonable approach to cardiac avoidance in patients requiring RNI, including those receiving anthracyclines and HER2-directed therapy. Larger cohorts with longer follow-ups will be needed to validate these findings.</p></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 10","pages":"Article 101581"},"PeriodicalIF":2.2000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452109424001441/pdfft?md5=f086438632f3ea7e61ec0506485e2fd3&pid=1-s2.0-S2452109424001441-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452109424001441","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Regional nodal irradiation (RNI) for breast cancer yields improvements in disease outcomes, yet comprehensive target coverage often increases cardiac radiation therapy (RT) dose. Volumetric modulated arc therapy (VMAT) may mitigate high-dose cardiac exposure, although it often increases the volume of low-dose exposure. The cardiac implications of this dosimetric configuration (in contrast to historic 3D conformal techniques) remain uncertain.

Methods and Materials

Eligible patients receiving adjuvant RNI using VMAT for locoregional breast cancer were prospectively enrolled in an IRB-approved study. Echocardiograms were performed prior to RT, at the conclusion of RT, and 6 months following RT. Echocardiographic parameters were measured by a single reader and measures were compared pre- and post-RT via the signed-rank test. Changes in echocardiographic parameters over time were compared to mean and max heart doses via the Spearman correlation test.

Results

Among 19 evaluable patients (median age 38 years), 89% (n = 17) received doxorubicin and 37% (n = 7) received trastuzumab/pertuzumab combination therapy. All patients received VMAT-based whole-breast/chest wall and RNI. The average mean heart dose was 456 cGy (range, 187-697 cGy) and the average max heart dose was 3001 cGy (1560-4793 cGy). Among salient echocardiographic parameters, no significant decrement in cardiac function was observed when comparing pre-RT to 6 months post-RT: mean left ventricular ejection fraction (LVEF) was 61.8% (SD 4.4%) pre-RT and 62.7% (SD 3.8%) 6 months post-RT (P = .493); mean global longitudinal strain (GLS) was –19.3% (SD 2.2%) pre-RT and –19.6% (SD 1.8%) 6 months post-RT (P = .627). No individual patient exhibited reduced LVEF or sustained decrement in GLS. No correlations were observed for changes in LVEF or GLS when compared to mean or maximum heart doses (P > .1 for all).

Conclusions

VMAT for left-sided RNI yielded no significant early decrement in echocardiographic parameters of cardiac function, including LVEF and GLS, within this limited cohort. No patient exhibited significant LVEF changes, and none exhibited sustained decrements in GLS. VMAT may be a reasonable approach to cardiac avoidance in patients requiring RNI, including those receiving anthracyclines and HER2-directed therapy. Larger cohorts with longer follow-ups will be needed to validate these findings.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用容积调制弧线疗法进行乳腺癌区域结节照射后的超声心动图功能结果
目的 乳腺癌区域结节照射(RNI)可改善疾病预后,但全面的靶区覆盖往往会增加心脏放疗(RT)剂量。容积调强弧形疗法(VMAT)可减轻高剂量心脏照射,但往往会增加低剂量照射量。这种剂量配置(与历史悠久的三维适形技术相比)对心脏的影响仍不确定。方法和材料一项经 IRB 批准的研究前瞻性地招募了使用 VMAT 辅助 RNI 治疗局部乳腺癌的合格患者。分别在 RT 术前、RT 术后和 RT 术后 6 个月进行超声心动图检查。超声心动图参数由一名读片员测量,并通过符号秩检验比较RT前后的测量结果。结果19名可评估患者(中位年龄38岁)中,89%(n=17)接受多柔比星治疗,37%(n=7)接受曲妥珠单抗/哌妥珠单抗联合治疗。所有患者都接受了基于VMAT的全胸/胸壁和RNI治疗。平均心脏剂量为456 cGy(范围为187-697 cGy),平均最大心脏剂量为3001 cGy(1560-4793 cGy)。在突出的超声心动图参数中,将射频消融术前与射频消融术后 6 个月进行比较,未观察到心脏功能的显著下降:射频消融术前平均左室射血分数(LVEF)为 61.8%(标清 4.4%),射频消融术后 6 个月为 62.7%(标清 3.8%)(P = .493);射频消融术前平均整体纵向应变(GLS)为 -19.3%(标清 2.2%),射频消融术后 6 个月为 -19.6%(标清 1.8%)(P = .627)。没有患者表现出 LVEF 降低或 GLS 持续下降。与平均或最大心脏剂量相比,未观察到 LVEF 或 GLS 的变化存在相关性(均为 P > .1)。没有患者的 LVEF 出现明显变化,也没有患者的 GLS 出现持续下降。对于需要接受 RNI 治疗的患者,包括接受蒽环类药物和 HER2 导向治疗的患者,VMAT 可能是一种合理的心脏回避方法。要验证这些研究结果,还需要更大范围、更长时间的随访。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Advances in Radiation Oncology
Advances in Radiation Oncology Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
4.60
自引率
4.30%
发文量
208
审稿时长
98 days
期刊介绍: The purpose of Advances is to provide information for clinicians who use radiation therapy by publishing: Clinical trial reports and reanalyses. Basic science original reports. Manuscripts examining health services research, comparative and cost effectiveness research, and systematic reviews. Case reports documenting unusual problems and solutions. High quality multi and single institutional series, as well as other novel retrospective hypothesis generating series. Timely critical reviews on important topics in radiation oncology, such as side effects. Articles reporting the natural history of disease and patterns of failure, particularly as they relate to treatment volume delineation. Articles on safety and quality in radiation therapy. Essays on clinical experience. Articles on practice transformation in radiation oncology, in particular: Aspects of health policy that may impact the future practice of radiation oncology. How information technology, such as data analytics and systems innovations, will change radiation oncology practice. Articles on imaging as they relate to radiation therapy treatment.
期刊最新文献
Outcomes After Stereotactic Body Radiation for Hepatocellular Carcinoma in Patients With Child-Pugh A Versus Child-Pugh B/C Cirrhosis Editorial board Pegylated Interferon Combined With Low-Dose Total Skin Electron Beam Therapy for Advanced Stage Mycosis Fungoides: Two Case Reports and Literature Review Cone Beam Computed Tomography-Based Online Adaptive Radiation Therapy of Esophageal Cancer: First Clinical Experience and Dosimetric Benefits Prospective Trial on the Impact of Weekly Cone Beam Computed Tomography-Guided Correction on Mean Heart Dose in Breast Cancer Breath-Hold Radiation Therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1